Is a HDE file a compressed RAW file? If not, how is it different?.HDE is applied at the point of offloading files from the original camera media. For earlier ARRI cameras when an ARRIRAW image is encoded as HDE, the file extension changes from. The encoding happens when files are copied from a Compact Drive or Capture Drive.įor the ALEXA 35 workflow Device Manager provides HDE MXF files from ARRIRAW MXF source files. UPDATE: ARRIRAW Open Gate 4.6K can be encoded at over 50 fps on a Mac Pro (2019 Intel model)., and at over 100 fps on a Mac Studio or MacBook Pro (2022 M1 Max model). HDE is designed to be high performance for encoding and decoding, and is dependent on CPU power. When stored as HDE, this becomes 1203GB/hour. For example, ARRIRAW 4.6K 3:2 Open Gate is normally 2006GB/hour. HDE typically results in a file that is 60% of the original ARRIRAW file size. HDE can be used on ARRIRAW images of any resolution. HDE encoding is completely lossless - when an HDE image is decoded, it is a bit-for-bit perfect match to the original image. ARRIRAW images encoded with HDE are typically around 60% of the original size. It is an encoding technique that is optimised for Bayer pattern images. An uncompressed ARRIRAW file can be reduced to a HDE file size not much larger than a corresponding ProRes 4444 XQ mezzanine file, while retaining all original pixel values that were encoded. Uncompressed RAW data costs more to transport and store than compressed ProRes files. HDE is a free workflow accelerator built into CODEX Device Manager when working with ARRIRAW on CODEX capture media.įor ALEXA Mini and AMIRA recording ARRIRAW to CFast media, users can purchase a licence to enable HDE for their workflows. HDE is an easy to use tool for large format workflows to control the ever-increasing data footprint of RAW video images. High Frame Rate (HFR) and High Dynamic Range (HDR) add to this large format data footprint, leading to significant cost increases as well as storage and transmission challenges. Studios are demanding 4K and RAW image data to archive and future-proof the negative. HDE can reduce the overall storage size of RAW images by up to a 2:1 ratio. However, despite this caveat, the study demonstrates the potential long-lasting benefits of PD-1 blockade administered before surgery.CODEX High Density Encoding (HDE) provides bit-exact data reduction of uncompressed camera ARRIRAW files through encoding. The authors acknowledge a limitation of the study as the small number of patients. Similar to the observation in the original study, no severe side effects resulted from the therapeutic regimen, and no patients in the study had to delay surgery due to side effects. Seven of the eleven patients without MPR still achieved five-year survival however, recurrence occurred more often in these patients. One patient with MPR died from a non-cancer-related cause. The researchers reported nine patients with MPR, and eight of these patients remained alive and disease-free five years post-treatment. In patients achieving MPR, less than 10% of the resected tissue contains residual tumor, indicating that the neoadjuvant nivolumab administered before surgery effectively killed tumor cells. The study also evaluated major pathological response ( MPR) in the resected lung tissue following surgery. This means that 60% of the patients had not experienced tumor regression survival five years after surgery. Further, 60% of the participants achieved five-year recurrence-free survival. This high survival rate is notable, as the survival of patients with NSCLC receiving surgery alone ranges from 36 – 68%. The study revealed that 80% of the participants remained alive. At the time of analysis, participants had been monitored for an average of 63 months. The trial eligibility guidelines allowed some patients (26%) to receive adjuvant chemotherapy in addition to nivolumab. Most (86%) of the participants reported a history of smoking. The cohort consisted of eleven women and ten men at an average age of 67. The study included 21 patients with Stage I–IIIA NSCLC. The authors note that their new study delivers the longest follow-up data for neoadjuvant PD-1 blockade to date. Fast forward to February 2023, the same team of researchers published updated results in Clinical Cancer Research, providing valuable clinical outcomes from the trial originally reported on five years earlier.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |